Text Size

Potential neuroprotective effects of an LSD1 inhibitor in retinal ganglion cells via p38 MAPK activity

Tsutsumi T., Iwao K., Hayashi H., Kirihara T., Kawaji T., Inoue T., Hino S., Nakao M., Tanihara H.


  • 2016
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Glaucoma

  • Affiliations

    Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; Department of Applied Biochemistry, School of Pharmacy Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; Translational Science R&D Division, Santen Pharmaceutical Co. Ltd, Osaka, Japan; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022